Dr. Mohammed T. Masri, MD

Dr. Masri practices at McLaren Oakland in Pontiac, Michigan, part of McLaren Health Care.

Dr. Masri's NPI, 1669409439, was assigned on June 27, 2006. Dr. Masri holds Michigan license 4301106637.

Dr. Masri's primary practice is McLaren Oakland, at 50 N Perry St, Pontiac, MI 48342 in Oakland County. The practice phone is (248) 338-5000.

Dr. Masri's primary practice is McLaren Oakland in Pontiac, Michigan, part of McLaren Health Care. Dr. Masri is also affiliated with Trinity Health Oakland Hospital. The medical group on file is McLaren Oakland. Dmand AI also links Dr. Masri to 3 more hospitals, 3 group practices and clinics, 2 medical groups and 1 skilled nursing facility, each named with a free account. Dr. Masri's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Masri practices, 9 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Masri's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Masri is licensed in Michigan.

CMS data shows 809 Medicare services from Dr. Masri across 8 procedure codes in 2024, for 252 Medicare patients. Medicare paid $68,886 for them.

CMS counts 252 Medicare patients who saw Dr. Masri in 2024. The largest group is 65 to 74, with 118 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Masri's median patient age at 71, with 57% women.

In 2024, Dr. Masri wrote 873 Medicare Part D claims for 175 patients. 72% of them were for generic drugs. CMS names the drug for 495 of them, across 20 drugs with 11 or more claims each, at $1,114,226 in total drug cost. In 2023, CMS named 397 claims across 17 drugs.

Dr. Masri accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Masri as offering telehealth.

Dmand AI links 1 paper to Dr. Masri in 2016. Dr. Masri's most frequent co-authors are James Richard Berenson, MD, Emad N. Ibrahim, MD and Jonathan Scott Treisman, MD.

Dmand AI links Dr. Masri to 10 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 884 general payments to Dr. Masri from 71 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 62% of the total. Celgene Corporation paid the most, $3,004. It also lists 1 research payment totaling $190 in 2018.